Your browser is no longer supported. Please, upgrade your browser.
Settings
BEAM Beam Therapeutics Inc. daily Stock Chart
BEAM [NASD]
Beam Therapeutics Inc.
Index- P/E- EPS (ttm)-2.68 Insider Own13.61% Shs Outstand30.73M Perf Week21.69%
Market Cap1.27B Forward P/E- EPS next Y-2.53 Insider Trans0.00% Shs Float24.30M Perf Month-5.63%
Income-106.20M PEG- EPS next Q-0.53 Inst Own51.40% Short Float8.29% Perf Quarter18.40%
Sales0.02M P/S52938.33 EPS this Y22.40% Inst Trans0.21% Short Ratio5.32 Perf Half Y-1.99%
Book/sh8.51 P/B2.78 EPS next Y0.40% ROA- Target Price32.00 Perf Year-
Cash/sh4.71 P/C5.01 EPS next 5Y- ROE- 52W Range13.00 - 31.80 Perf YTD25.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.72% Beta-
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin- 52W Low81.69% ATR1.88
Employees134 Current Ratio8.30 Sales Q/Q- Oper. Margin- RSI (14)52.71 Volatility9.07% 7.28%
OptionableNo Debt/Eq0.03 EPS Q/Q-182.50% Profit Margin- Rel Volume1.16 Prev Close24.10
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume379.03K Price23.62
Recom1.40 SMA206.76% SMA50-6.19% SMA2006.81% Volume438,213 Change-1.99%
Aug-05-20Initiated William Blair Outperform
Mar-02-20Initiated Wedbush Outperform $32
Mar-02-20Initiated JP Morgan Overweight $31
Mar-02-20Initiated Jefferies Buy $32
Mar-02-20Initiated Barclays Overweight $32
Aug-04-20 07:15AM  
Jul-30-20 06:30AM  
Jun-15-20 06:00AM  
May-26-20 06:30AM  
May-18-20 06:21PM  
May-12-20 01:40PM  
06:30AM  
May-06-20 10:25AM  
Apr-28-20 04:35PM  
04:35PM  
Mar-30-20 06:30AM  
Mar-16-20 07:00AM  
Mar-05-20 01:53PM  
Feb-11-20 07:41AM  
06:30AM  
Feb-05-20 07:05PM  
Jan-27-20 07:24AM  
Jan-25-20 05:00AM  
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.